A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.

Guillermo Garcia-Manero,Meagan A. Jacoby,David A. Sallman,Tae Han,Jeanmarie Guenot,Eric J. Feldman

A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.

2019

Guillermo Garcia-Manero
Meagan A. Jacoby
David A. Sallman
Tae Han
Jeanmarie Guenot
Eric J. Feldman

TPS7071Background: The CD33 antigen is expressed on myeloblasts in approximately 75% of patients with myelodysplastic syndromes (MDS) and is also expressed on immunosuppressive myeloid-derived supp...

Keywords:

CD33
Pathology
Antigen
Myelodysplastic syndromes
Oncology
Internal medicine
Medicine
in patient
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations